Immunotherapy for Colorectal Cancer: A Meta-Analysis
Author Information
Author(s): Rao Benqiang, Han Minyan, Wang Lei, Gao Xiaoyan, Huang Jun, Huang Meijin, Liu Huanliang, Wang Jianping
Primary Institution: The Sixth Affiliated Hospital, Sun Yat-sen University
Hypothesis
Does active specific immunotherapy (ASI) improve clinical outcomes in advanced colorectal cancer and suspected minimal residual colorectal cancer?
Conclusion
ASI shows promising clinical responses in patients with suspected minimal residual colorectal cancer, but limited effectiveness in advanced colorectal cancer.
Supporting Evidence
- 1375 patients with suspected minimal residual CRC showed improved overall survival with ASI.
- Statistical significance was achieved for disease-free survival in stage III suspected minimal residual CRC.
- Only 1.68% of advanced CRC patients showed clinical responses to ASI.
Takeaway
This study looked at how a special treatment called immunotherapy helps people with colorectal cancer. It found that it works better for some patients who might still have small amounts of cancer left after surgery.
Methodology
A meta-analysis of studies on ASI in colorectal cancer was conducted, focusing on overall survival and disease-free survival.
Potential Biases
Some studies had unclear randomization and allocation concealment, leading to potential bias.
Limitations
The study included only human trials published in English and excluded case studies and studies with fewer than three patients.
Participant Demographics
The study involved 2031 patients, with 1375 in the suspected minimal residual CRC group and 656 in the advanced CRC group.
Statistical Information
P-Value
0.007
Confidence Interval
0.63-0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website